库欣病 (CD) 患者的骨矿物质密度 (BMD) 恢复通常缓慢，而抗骨质疏松药物对于手术后已实现生化缓解的年轻 CD 患者的有效性尚不清楚。因此，我们旨在探讨双磷酸盐是否可以帮助加速缓解的年轻CD患者骨质疏松的恢复。我们回顾性入组了34名术后实现生化缓解的年轻CD患者。所有患者术前均患有骨质疏松症，术后分为双膦酸盐治疗组（16例）和未接受双膦酸盐治疗组（18例）。在诊断时和成功肿瘤切除一年后收集临床数据、BMD（Z 值）和骨转换标志物。随访时两组腰椎 Z 值均较基线略有改善，但这种改善在统计上并不显着。随访时两组之间没有观察到显着差异。术后一年，两组骨形成标志物（OC和P1NP）均显着高于基线。然而，一年随访时，双膦酸盐治疗组的 OC 和 P1NP 低于对照组。未接受双膦酸盐治疗组随访时β-CTX高于基线，而双膦酸盐治疗组手术前后无显着差异。年轻库欣病合并骨质疏松患者可能无法从双膦酸盐中获益实现生化缓解后第一年骨质疏松恢复的治疗。版权所有 © 2024 Sun、Sun、Ye 和Zhang。

Patients with Cushing's disease (CD) often experience slow recovery of bone mineral density (BMD), and the effectiveness of anti-osteoporosis drugs in young CD patients who have achieved biochemical remission after surgery is not well understood. Therefore, we aimed to explore whether bisphosphonates could help accelerate the recovery of osteoporosis in young CD patients with remission.We retrospectively enrolled 34 young patients with CD who achieved postoperative biochemical remission. All patients suffered from osteoporosis before surgery and were divided into postoperative bisphosphonate treatment group (16 cases) and without bisphosphonate treatment group (18 cases). Clinical data, BMD (Z Value), and bone turnover markers were collected at the time of diagnosis and one year after successful tumor resection.The Z values in the lumbar spine showed slight improvement in both groups at follow-up compared to baseline, but this improvement was not statistically significant. There was no significant difference observed between the two groups at follow-up. One year after operation, bone formation markers (OC and P1NP) were significantly higher than those at baseline in both groups. However, OC and P1NP in the bisphosphonate treatment group were lower than those in control group at one year follow-up. In without bisphosphonate treatment group, β-CTX from follow-up visit was higher than that at baseline, while no significant difference was observed in the bisphosphonate treatment group before and after surgery.Young patients with Cushing's disease combined with osteoporosis might not benefit from bisphosphonate therapy for osteoporosis recovery in the first year after achieving biochemical remission.Copyright © 2024 Sun, Sun, Ye and Zhang.